• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high- risk malignant blood diseases].异基因造血干细胞移植前清髓剂量预处理治疗12例55岁以上高危恶性血液病患者的临床研究
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):708-11. doi: 10.3760/cma.j.issn.0253-2727.2016.08.016.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.非清髓性干细胞移植及针对恶性和非恶性疾病的细胞治疗
Transpl Immunol. 2005 Aug;14(3-4):207-19. doi: 10.1016/j.trim.2005.03.009. Epub 2005 Apr 26.
4
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.异基因造血干细胞移植中清髓性与非清髓性/减低强度方案的比较综述。
Balkan Med J. 2017 Jan;34(1):1-9. doi: 10.4274/balkanmedj.2017.0055. Epub 2017 Jan 5.
5
Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.非清髓性干细胞移植及供体淋巴细胞输注用于治疗癌症和危及生命的非恶性疾病。
Rev Clin Exp Hematol. 2001 Jun;5(2):135-46. doi: 10.1046/j.1468-0734.2001.00036.x.
6
Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.接受异基因造血细胞移植治疗恶性和非恶性疾病的儿科和青少年患者移植后早期毒性对生存的影响：识别风险并优化结局
Biol Blood Marrow Transplant. 2016 Aug;22(8):1525-1530. doi: 10.1016/j.bbmt.2016.05.012. Epub 2016 May 17.
7
Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.来那度胺联合全身照射为基础的清髓性预处理异基因造血干细胞移植治疗的 1 期临床研究
Int J Hematol. 2021 Jun;113(6):877-883. doi: 10.1007/s12185-021-03109-7. Epub 2021 Mar 1.
8
[Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation-New Opinion about Hematopoietic Stem Cell Transplantation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Mar;9(1):80-85.
9
Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.“微移植”综述：非清髓性异基因造血干细胞移植
Int J Hematol. 2003 Jan;77(1):3-14. doi: 10.1007/BF02982597.
10
Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals.非清髓性干细胞移植治疗癌症和危及生命的非恶性疾病：过去的成就与未来目标。
Transfus Apher Sci. 2002 Oct;27(2):159-66. doi: 10.1016/s1473-0502(02)00038-1.

本文引用的文献

1
Acute myeloid leukemia in the elderly: do we know who should be treated and how?老年急性髓系白血病：我们知道哪些患者应接受治疗以及如何治疗吗？
Leuk Lymphoma. 2014 May;55(5):979-87. doi: 10.3109/10428194.2013.828348. Epub 2013 Aug 28.
2
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.70 岁或以上血液系统恶性肿瘤患者接受异基因造血干细胞移植的结局。
Biol Blood Marrow Transplant. 2013 Sep;19(9):1374-80. doi: 10.1016/j.bbmt.2013.06.008. Epub 2013 Jun 18.
3
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.氟达拉滨、卡莫司汀、马法兰和抗胸腺细胞球蛋白用于成人降低毒性预处理和同种异体干细胞移植：结果取决于疾病风险指数，但与年龄、合并症评分、供体类型或人类白细胞抗原错配无关。
Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.
4
Do different conditioning regimens really make a difference?不同的预处理方案真的有区别吗？
Hematology Am Soc Hematol Educ Program. 2012;2012:237-45. doi: 10.1182/asheducation-2012.1.237.
5
Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.优化急性髓细胞白血病异基因干细胞移植的预处理方案；仍需关注剂量强度。
Best Pract Res Clin Haematol. 2011 Sep;24(3):369-79. doi: 10.1016/j.beha.2011.05.002. Epub 2011 Jun 24.
6
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.年龄对缓解后接受低强度造血细胞移植的老年急性髓系白血病或骨髓增生异常综合征患者的预后的影响。
J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.
7
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.60 岁以上患者的低强度预处理造血干细胞移植：高龄不会损害血液系统恶性肿瘤的转归。
Biol Blood Marrow Transplant. 2010 Jun;16(6):792-800. doi: 10.1016/j.bbmt.2009.12.537. Epub 2010 Jan 13.
8
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.作为急性髓系白血病/骨髓增生异常综合征（AML/MDS）移植前预处理疗法，每日一次静脉注射白消安和氟达拉滨（静脉注射Bu-Flu）与静脉注射白消安和环磷酰胺（静脉注射BuCy2）相比具有优势。
Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84. doi: 10.1016/j.bbmt.2008.03.009.
9
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.接受异基因造血细胞移植的急性髓系白血病或骨髓增生异常综合征患者基于合并症和疾病状态的结局风险分层
J Clin Oncol. 2007 Sep 20;25(27):4246-54. doi: 10.1200/JCO.2006.09.7865. Epub 2007 Aug 27.
10
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.造血细胞移植（HCT）特异性合并症指数：一种用于异基因造血细胞移植前风险评估的新工具。
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.

[Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high- risk malignant blood diseases].

作者信息

Lu Y, Wu T, Liu D Y, Cao X Y, Xiong M, Zhang J P, Zhou J R, Lu D P

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):708-11. doi: 10.3760/cma.j.issn.0253-2727.2016.08.016.

DOI:10.3760/cma.j.issn.0253-2727.2016.08.016
PMID:27587256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7348528/
Abstract
摘要